Nanjing Pharmaceutical Co (SHSE:600713) Construction In Progress: ¥374 Mil (As of Mar. 2026)


SHSE:600713 Nanjing Pharmaceutical Co Ltd SHSE:600713
59 GF Score
Price ¥5.05
GF Value ¥4.50
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nanjing Pharmaceutical Co Construction In Progress?

Nanjing Pharmaceutical Co SHSE:600713 -1.94% 59 Construction In Progress is ¥374 Mil as of Mar. 2026. GuruFocus rates SHSE:600713 with a GF Score™ of 59/100 and a GF Value™ of ¥4.50 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Nanjing Pharmaceutical Co's quarterly construction in progress declined from Sep. 2025 (¥382 Mil) to Dec. 2025 (¥350 Mil) but then increased from Dec. 2025 (¥350 Mil) to Mar. 2026 (¥374 Mil).

Nanjing Pharmaceutical Co's annual construction in progress increased from Dec. 2023 (¥130 Mil) to Dec. 2024 (¥237 Mil) and increased from Dec. 2024 (¥237 Mil) to Dec. 2025 (¥350 Mil).

Nanjing Pharmaceutical Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Nanjing Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Pharmaceutical Co Construction In Progress Chart

Nanjing Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 153.40 80.23 130.08 237.27 349.69

Nanjing Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 262.93 342.99 382.26 349.69 374.30
SHSE:600713
59GF Score
Nanjing Pharmaceutical Co Ltd SHSE:600713
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥374 Mil mean?
Nanjing Pharmaceutical Co (SHSE:600713) has a Construction In Progress of ¥374 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Nanjing Pharmaceutical Co and its competitors.
Is Nanjing Pharmaceutical Co's Construction In Progress too high?
Nanjing Pharmaceutical Co's current Construction In Progress is ¥374 Mil. Overall, Nanjing Pharmaceutical Co has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Pharmaceutical Co's Construction In Progress compare to LLY and JNJ?
Nanjing Pharmaceutical Co's Construction In Progress of ¥374 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Nanjing Pharmaceutical Co and its competitors. Nanjing Pharmaceutical Co's current Construction In Progress is ¥374 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Pharmaceutical Co (SHSE:600713) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.50, compared to a current price of ¥5.05 — trading 12.2% above its estimated fair value. The current Construction In Progress is ¥374 Mil. Nanjing Pharmaceutical Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Nanjing Pharmaceutical Co (SHSE:600713), the current Construction In Progress is ¥374 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing Pharmaceutical Co (SHSE:600713) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.05 is trading 12.2% above its estimated GF Value™ of ¥4.50. GuruFocus considers Nanjing Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600713:

  • Construction In Progress: ¥374 Mil
  • GF Value™: ¥4.50 vs. price of ¥5.05 (12.2% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanjing Pharmaceutical Co Business Description

Address No. 55, Andemen Street, Building 2, Yuhuatai District, Jiangsu Province, Nanjing, CHN, 210002
Nanjing Pharmaceutical Co Ltd is engaged in the pharmaceutical service business.
59GF Score

Get the complete analysis for SHSE:600713

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.05
Price
¥4.50
GF Value